Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) Other Operating Expenses (2020 - 2026)

Maxcyte has reported Other Operating Expenses over the past 6 years, most recently at -$9.6 million for Q4 2025.

  • Quarterly Other Operating Expenses rose 21.8% to -$9.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$45.3 million through Dec 2025, up 5.5% year-over-year, with the annual reading at -$46.5 million for FY2025, 2.61% up from the prior year.
  • Other Operating Expenses was -$9.6 million for Q4 2025 at Maxcyte, up from -$12.4 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $8.3 million in Q4 2023 and troughed at -$13.2 million in Q3 2024.
  • The 5-year median for Other Operating Expenses is $3.4 million (2021), against an average of -$1.3 million.
  • Year-over-year, Other Operating Expenses soared 75.49% in 2021 and then tumbled 263.61% in 2024.
  • A 5-year view of Other Operating Expenses shows it stood at $4.5 million in 2021, then surged by 39.81% to $6.3 million in 2022, then soared by 32.15% to $8.3 million in 2023, then tumbled by 248.56% to -$12.3 million in 2024, then rose by 21.8% to -$9.6 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Other Operating Expenses are -$9.6 million (Q4 2025), -$12.4 million (Q3 2025), and -$12.4 million (Q2 2025).